©NIJPP
Publications 2025

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

NEWPORT INTERNATIONAL JOURNAL OF PUBLIC HEALTH AND PHARMACY (NIJPP)

Volume 6 Issue 1 Page 20-26, 2025

https://doi.org/10.59298/NIJPP/2025/612026

Engineering Novel Drug Formulations: Challenges and Opportunities

Tugonza Akiro F.

Faculty of Science and Technology Kampala International University Uganda

ABSTRACT

The development of novel drug formulations is a crucial aspect of pharmaceutical research, ensuring enhanced drug efficacy, bioavailability, and patient compliance. Despite significant advancements, challenges such as poor solubility, stability issues, and regulatory constraints continue to hinder the formulation of new drugs. This paper examines fundamental concepts in drug formulation, highlighting the limitations of conventional approaches and the emergence of advanced technologies, including nanotechnology-based formulations. Innovations in targeted delivery systems and the integration of multidisciplinary expertise are essential for overcoming these challenges. Future opportunities lie in the application of cutting-edge technologies and strategic collaborations between pharmaceutical scientists and regulatory bodies to enhance the effectiveness of drug formulations.

Keywords: Drug Formulation, Bioavailability, Nanotechnology, Drug Delivery Systems, Pharmaceutical Innovations, Stability Issues.

INTRODUCTION

Innovation in advanced drug dosage forms plays a beneficial cornerstone not only in present-day pharmaceutical developments but also in future patient therapy promising. The truth that the bioavailability and safety of a drug are reliant on its formulation gives drug formulation a fundamental rank in drug improvement. More and more frequently, the success of a novel drug candidate in clinical trials is uncovered not by its effectiveness but by fundamental challenges with its delivery system. Bioavailability issues, coupled with poor formulation adaptation, signify that a substantial modulation of formulation or a design of an entirely new formulation might be requisite [1, 2]. Current attempts to drug modifications have caused a technological widening of formulation such as extended-release dosage forms or a casting into the form of fixed-dose combinational drugs. The pharmaceutical industry has gotten over the more rugged shielding of lower R&D productivity post-blockbuster era mainly due to reaching more medium rates of NME approval. So, the opportunity of admiring highly innovative projects that would own a low-medium technological maturity concerning the state-of-the-art that is characterized by a broad range of possible formulation routes is more than ever welcomed. There are numerous formulation modalities appropriate for every specific drug with various timelines for their applicability. To design a highly inventive drug formulation, one should build an advanced strategy considering multiple specific aspects [3, 4].

Fundamentals of Drug Formulation

Formulation is the development of a biologically effective preparation into a usable dose or delivery system. Various factors when formulating a drug, including the form in which the drug will be produced as well as the method of administration. The formulated process bans not only the active compound required by the drug but also compounds that will enable the active compound to take effect when administered. It is important to understand the physical and chemical characteristics that will be effective

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

in drug design, ie, the actual formation of the drug in a physical and molecular context. This is because an understanding of the structure of a compound can allow an assessment of the stability, bioavailability, and effectiveness of that compound. As understanding the physicochemical properties will allow for these assessments, it is possible to then prepare formulations that maximize the pharmacological effect of the drug compound [5, 6]. An understanding of dosage forms of drugs and their connection to the appropriate route of administration is also mandatory. Common dosage forms are solids, liquids, and smoke signals, actually ingested as pills, while liquids are given as injections or supplements. Drugs such as protein complexes may be administered as aerosols in the lungs. Administering a drug to the intended organ is important in achieving good bioavailability, as the body must circulate completely through the plasma and interact with its goal. Dosage form production is thus also vitally important in the formulated process. Commonly prepared concepts of formulation stability, solubility, bioavailability, and evaluation of formulated products will be examined, with practical methods of preparing, assessing, and optimizing formulations for the experienced researcher [7, 8].

Basic Concepts in Drug Formulation

Before venturing into the challenges and opportunities governing the engineering of novel drug formulations, it is critical to understand the basic concepts in this field. Researchers, as well as practitioners in the pharmaceutical and medical sectors, should already have a grasp of the primary concepts and terminologies associated with drug delivery systems. At its simplest, a drug delivery system is a formulation or a device constructed to transport a pharmaceutical compound in the body. The compound is released by design to attain a predetermined drug concentration level with the object of treating the underlying medical condition. Excipients in such a system play an essential role and are as important as the active drug substance. Despite different mechanisms of action, excipients can be designed to help the stability of the drug, altering its release profile or improving its bioavailability. All these terms have been developed to describe the pharmacokinetics and pharmacodynamics of a therapeutic system, and a good formulation strategy is developed when these concepts are well understood. Typically, research and development in drug delivery is carried out by a team of people with different backgrounds, including biologists, pharmacists, chemists, and engineers, which can make communication and understanding of all aspects of the problem very complex. Moreover, drug delivery is essentially a multiphase problem and can be dealt with using various multiphase phenomena, further complicating problem-solving strategies. Understanding the basic definitions and concepts of these subjects is essential and is, therefore, presented in this paper. In addition, the legislation regarding the registration of new drugs is becoming increasingly stringent and complicated and requires considerable investment and effort. Modern drug formulation usually takes a long time—often a decade—until the final industrial formulation is developed. Therefore, the difficulties and challenges that need to be faced are primarily directed towards those issues. This paper is intended to give an insight into the basic concepts around the drug formulation problem, which, hopefully, will enable more precise decisions and solutions to be made in the future [9, 10].

Challenges in Conventional Drug Formulations

The challenges involved in conventional drug formulations are significant, as they play a vital part in the development of the medicines themselves. Many drug developers often overlook the complexities involved in the delivery of active pharmaceutical ingredients (APIs), instead focusing their entire funding and attention on the development of the medicines themselves. However, no matter the effectiveness of the API, if there are issues surrounding patient compliance, bioavailability, and stability through processing and storage, then its efficacy will inevitably be compromised. This, in turn, limits the commercial viability of any drug candidate, as at its core, it simply won't work as intended if formulated inadequately. Traditional methods of drug delivery also have considerable limitations, particularly when it comes to the interactions between the formulation of the drug and the matrix it is delivered within. This means that the uptake and subsequent bioavailability of the API by the patient will be unnecessarily curtailed. Furthermore, these limitations can also impact the cost and risk involved in early drug development, as API commonly needs to be reformulated several times to obtain the desired performance [11, 12]. Pharmaceutical additives and the excipients chosen to structure a drug formulation play a major role in the efficacy of the active pharmaceutical ingredient dosage form. However, formulations are viewed at best as simple systems from regulatory authorities and are closely guarded as intellectual property by the pharmaceutical industry. The global pharmaceutical market compared to other markets

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

will be analyzed from an economic point of view. The World Health Organization estimates an increase in the global market from 250 billion USD in 2003 to 400 billion USD in 2008, with a global growth of 30% since 2003. In 2002, 62% of the global market came from the USA, 20% from Europe and 5% from Germany, whereas Asia had only 5% of the world turnover. Diverse ethical and legislative factors that influence the pharmaceutical industry will also be analyzed [13, 14].

Stability Issues

Stability issues are among the most important when considering the finalisation of any pharmaceutical development project. The reasons behind this are threefold: (a) it is a regulatory requirement that stability studies be carried out for a finished pharmaceutical product, and the amount and detail of such studies increase substantially with the importance (in terms of potential safety and benefit) of the novel drug formulation and with the magnitude and duration of the intended use (b) the safety and therapeutic efficacy of an active ingredient can be compromised by poor stability and (c) in practical terms, there is little point in producing a novel drug formulation which is inherently unstable. Degradation due to the inherent properties of the components in the formulation is by far the most common reason for the unacceptability of solid formulations, and in consequence, a vast amount of research has been done in the field. This paper focuses strictly on the stability issues rather than those related to mechanical strength, water solubility, or friability [15, 16]. Three main factors are generally considered in the stability of a solid formulation: (a) the effect of time, during which degradation processes may occur (b) the effect of conditions of storage, such as temperature, humidity and the incident of light and (c) the type of stability under consideration, which is usually divided into chemical and physical stability, although the boundaries between these two aspects of stability are not always well defined, as the examples later reveal. It should be stated here, of course, that unspoiled formulation of any kind is unlikely to achieve the desired therapeutic outcome. It has been estimated, for example, that nearly one-third of the so-called old age pensioners in some countries pay regular visits to their medical practitioners, but not for new prescriptions, simply to replace spoiled pharmaceuticals. More fundamentally, possibly as many as 500,000 cases of infertility in India alone are due to the use of degraded injectable contraceptives [17, 18].

Advanced Techniques in Drug Formulation

The pharmaceutical sector is witnessing a transition in drug formulation methodologies, the advent of advanced technologies being the major reason. With the application of advanced techniques, which include targeted delivery systems, industrial innovation, nanoparticles, vetrospheres, etc., the horizon of drug formulation is broadening like it has never done before [19-25]. These novel techniques can offer answers to the challenges that arose in conventional drug formulations. It is expected that the pharmaceutical industry will soon move from the conventional approach of drug formulation towards a more innovative one for obtaining enhanced outcomes [26-29]. Currently, the focus is on the development of technologies for novel drug formulations, as compared to the development of the drug itself. A vital role in these innovations is being played by the convergence of technology with other scientific disciplines, primarily chemistry, life sciences, and engineering, thereby enhancing the quality of research and the competitiveness of products. The therapeutic outcomes are also being affected positively due to these advances in technologies [30-35]. Patient needs are being met in a better way, and the bioavailability of the drug is enhanced significantly. The origin of drug formulations can be traced back to the first intramuscular injection in the year 1893. Since then, this sector has evolved a lot, and it is now entering one of the most diverse fields in the pharmaceutical sector. Over 140 years have passed since the April afternoon when the wife of Dr. Heinrich Dreser, the chemist of a German dye-works, took up a remarkable thesis that has evolved uniquely in the industrial, biotechnological, and bioethical sectors of medicine [36-40]. Drug formulation has not merely been a process for Doctor Dresser, but it has been revolutionized into a whole new technology and has profoundly influenced every aspect of treatment. Had it not been for such an accidental human mistake, pharmaceutical companies would have lost a fortune that they have now put to work? IDES study predicts worldwide sales of drug formulation products to rise by 2011 to a remarkable 137 billion dollars, which is double from 2001 [41-45].

Nanotechnology-Based Formulations

Nanotechnology represents the harbinger of a new era in drug formulation strategies due to its ability to exploit various materials in the nanoscale range. The bonanza of nanomedicine spans across modalities, targeting and therapeutic effects on the molecular, cellular, and biological levels. Each modality offers a

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

distinctive set of physical and chemical properties that can enhance drug bioavailability, improve drug solubility, and extend the drug's half-life. Poorly soluble drugs have the tendency to have erratic and incomplete absorption, leading to a decrease in pharmacological effect [42-47]. Nanotechnology can be employed to facilitate the transport of drug molecules via the formulation of nanoparticles, nanocrystals, and liposomes. Indeed, a significant number of materials engineered at the nanoscale range have recently been added to FDA-approved drugs. The current broad implementation in nanomedicine is explained by the added values of nanoscale materials, impacting on various properties such as solubility, stability, half-life, and targeting strategy. Nanoscale materials can significantly enhance the solubility and, hence, the stability of drug molecules. One common approach is the use of Trojan nanoparticles that act as nanocarriers and improve drug transportation by creating complexes with the drug molecules. Due to their small size, nanocarriers can be transported to specific destinations in the body, such as the lymph nodes, tumors, or inflamed regions and consequently increase the drug's therapeutic effect. Exploiting transport capabilities toward these moribund compounds may help refrain from discarding a worthwhile drug [23, 24]. Regarding new entities such as nanoscale materials, FDA compliance is an arduous and lengthy process associated with substantial uncertainty. The complexities and unprecedented scope of the characterization, together with the rigorous regulations, significantly hamper normalization and commercialization. This being said, extensive efforts are currently engaged among academia and industry to converge pugnaciously on overcoming these regulatory hurdles. For instance, several collaborative efforts join forces between engineering, life-science, and legal or regulatory experts. Importantly, the innovative and transformative nature of nanotechnology promises to generate a synergetic effect that will overcome the barriers. Subsequently, there has been fast growth in the development of nanotechnology-based formulations in medicine [25, 26].

Future Perspectives and Opportunities

Since early civilization, people have sought natural remedies for diseases, making herbal medicines the oldest and most widely used globally. Current guidelines and challenges for developing anti-cancer drugs highlight traditional herbal medicine through literature and laboratory work. Most natural products, especially traditional herbal medicines, lack standardization to ensure safety and efficacy in pharmacology. Key guidelines for developing herbal drugs include biopharmaceutics, drug combination designs, and compound compatibility. Future challenges and innovations in formulation strategies emphasize the need for a united technical team skilled in pharmacology and pharmaceutical sciences to enhance traditional herbal medicine's reliability as safe drugs. This work offers strategic directions for research and development in formulating traditional herbal medicine. Additionally, attitudes towards pre-clinical safety and the validity of formulated drugs may improve their acceptance. Pharmaceutical scientists and pharmacologists should invest more time in this area, establishing a safer, more organized marketplace for remedies. Ultimately, this research encourages exploring new technological platforms in pharmaceutical sciences to assist pharmacologists in evaluating traditional herbal medicines from pharmacology to active compound-formulation compatibility [27,28].

CONCLUSION

The field of drug formulation is rapidly evolving, driven by the need to enhance drug efficacy and patient outcomes. While conventional formulation methods face challenges such as poor solubility and bioavailability, emerging technologies offer promising solutions. Advances in nanotechnology, targeted drug delivery, and interdisciplinary collaborations are reshaping pharmaceutical development. Regulatory considerations and stability concerns remain significant obstacles, necessitating continued research and industry cooperation. Future efforts should focus on integrating innovative formulation strategies with regulatory compliance to accelerate the availability of more effective and safer drug therapies for patients worldwide.

REFERENCES

1. Stielow M, Witczyńska A, Kubryń N, Fijałkowski Ł, Nowaczyk J, Nowaczyk A. The bioavailability of drugs—the current state of knowledge. Molecules. 2023 Dec 11;28(24):8038. mdpi.com
2. Rocha B, de Morais LA, Viana MC, Carneiro G. Promising strategies for improving oral bioavailability of poor water-soluble drugs. Expert Opinion on Drug Discovery. 2023 Jun 3;18(6):615-27. [HTML]

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

3. Gao J, Karp JM, Langer R, Joshi N. The future of drug delivery. Chemistry of Materials. 2023 Jan 24;35(2):359-63.
4. Wang L, Wang N, Zhang W, Cheng X, Yan Z, Shao G, Wang X, Wang R, Fu C. Therapeutic peptides: current applications and future directions. Signal transduction and targeted therapy. 2022 Feb 14;7(1):48. nature.com
5. Wang G, Chen Y, Xia Y, Song X, Ai L. Characteristics of probiotic preparations and their applications. Foods. 2022 Aug 16;11(16):2472.
6. Guo P, Huang C, Yang Q, Zhong G, Zhang J, Qiu M, Zeng R, Gou K, Zhang C, Qu Y. Advances in formulations of microneedle system for rheumatoid arthritis treatment. International Journal of Nanomedicine. 2023 Dec 31:7759-84. tandfonline.com
7. Rouaz K, Chiclana-Rodríguez B, Nardi-Ricart A, Suñé-Pou M, Mercadé-Frutos D, Suñé-Negre JM, Pérez-Lozano P, García-Montoya E. Excipients in the paediatric population: A review. Pharmaceutics. 2021 Mar 13;13(3):387. mdpi.com
8. Vinarov Z, Abdallah M, Agundez JA, Allegaert K, Basit AW, Braeckmans M, Ceulemans J, Corsetti M, Griffin BT, Grimm M, Keszthelyi D. Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review. European Journal of Pharmaceutical Sciences. 2021 Jul 1;162:105812. sciencedirect.com
9. Park H, Otte A, Park K. Evolution of drug delivery systems: From 1950 to 2020 and beyond. Journal of Controlled Release. 2022 Feb 1;342:53-65.
10. Adepu S, Ramakrishna S. Controlled drug delivery systems: current status and future directions. Molecules. 2021 Sep 29;26(19):5905.
11. Chavda VP, Patel AB, Mistry KJ, Suthar SF, Wu ZX, Chen ZS, Hou K. Nano-drug delivery systems entrapping natural bioactive compounds for cancer: recent progress and future challenges. Frontiers in oncology. 2022 Mar 29;12:867655. frontiersin.org
12. Baryakova TH, Pogostin BH, Langer R, McHugh KJ. Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems. Nature Reviews Drug Discovery. 2023 May;22(5):387-409. nih.gov
13. Luo Y, Hong Y, Shen L, Wu F, Lin X. Multifunctional role of polyvinylpyrrolidone in pharmaceutical formulations. AAPS PharmSciTech. 2021 Jan;22:1-6.
14. Carou-Senra P, Rodríguez-Pombo L, Awad A, Basit AW, Alvarez-Lorenzo C, Goyanes A. Inkjet printing of pharmaceuticals. Advanced Materials. 2024 Mar;36(11):2309164. wiley.com
15. Bakker E, Hendrikse NM, Ehmann F, Van der Meer DS, Llinares Garcia J, Vetter T, Starokozhko V, Mol PG. Biomarker qualification at the European medicines agency: a review of biomarker qualification procedures from 2008 to 2020. Clinical Pharmacology & Therapeutics. 2022 Jul;112(1):69-80. wiley.com
16. Hsieh CM, Yang TL, Putri AD, Chen CT. Application of design of experiments in the development of self-microemulsifying drug delivery systems. Pharmaceuticals. 2023 Feb 13;16(2):283.
17. Fridgeirsdottir GA, Harris RJ, Dryden IL, Fischer PM, Roberts CJ. Multiple linear regression modeling to predict the stability of polymer–drug solid dispersions: comparison of the effects of polymers and manufacturing methods on solid dispersion stability. Molecular pharmaceutics. 2018 Mar 13;15(5):1826-41.
18. Nikodimos Y, Huang CJ, Taklu BW, Su WN, Hwang BJ. Chemical stability of sulfide solid-state electrolytes: stability toward humid air and compatibility with solvents and binders. Energy & Environmental Science. 2022;15(3):991-1033. researchgate.net
19. Malheiro V, Duarte J, Veiga F, Mascarenhas-Melo F. Exploiting Pharma 4.0 Technologies in the Non-Biological Complex Drugs Manufacturing: Innovations and Implications. Pharmaceutics. 2023 Oct 28;15(11):2545.
20. Atrooz O, Kerdari E, Mozafari MR, Reihani N, Asadi A, Torkaman S, Alavi M, Taghavi E. A Comparative Review of Tocosomes, Liposomes, and Nanoliposomes as Potent and Novel Nanonutraceutical Delivery Systems for Health and Biomedical Applications. Biomedicines. 2024 Sep 3;12(9):2002. mdpi.com

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

21. Miguel RD, Hirata AS, Jimenez PC, Lopes LB, Costa-Lotufo LV. Beyond formulation: Contributions of nanotechnology for translation of anticancer natural products into new drugs. Pharmaceutics. 2022 Aug 17;14(8):1722. mdpi.com
22. Hsu JF, Chu SM, Liao CC, Wang CJ, Wang YS, Lai MY, Wang HC, Huang HR, Tsai MH. Nanotechnology and nanocarrier-based drug delivery as the potential therapeutic strategy for glioblastoma multiforme: An update. Cancers. 2021 Jan 7;13(2):195. mdpi.com
23. Al-Thani AN, Jan AG, Abbas M, Geetha M, Sadasivuni KK. Nanoparticles in cancer theragnostic and drug delivery: A comprehensive review. Life sciences. 2024 Jul 9:122899. sciencedirect.com
24. Shringarpure M, Gharat S, Momin M, Omri A. Management of epileptic disorders using nanotechnology-based strategies for nose-to-brain drug delivery. Expert Opinion on Drug Delivery. 2021 Feb 1;18(2):169-85. researchgate.net
25. Paliwal R, Kumar P, Chaurasiya A, Kenwat R, Katke S, Paliwal SR. Development of nanomedicines and nano-similars: Recent advances in regulatory landscape. Current Pharmaceutical Design. 2022 Jan 1;28(2):165-77. [HTML]
26. Oksel Karakus C, Bilgi E, Winkler DA. Biomedical nanomaterials: applications, toxicological concerns, and regulatory needs. Nanotoxicology. 2021 Mar 16;15(3):331-51.
27. Rantanen J, Khinast J. The future of pharmaceutical manufacturing sciences. Journal of pharmaceutical sciences. 2015 Nov 1;104(11):3612-38.
28. Sadgrove NJ. Honest nutraceuticals, cosmetics, therapies, and foods (NCTFs): Standardization and safety of natural products. Critical Reviews in Food Science and Nutrition. 2022 Jun 1;62(16):4326-41.
29. Okechukwu PU, Okwesili FN, Parker EJ, Abubakar B, Emmanuel CO, Christian EO. Phytochemical and acute toxicity studies of *Moringa oleifera* ethanol leaf extract. *Int J Life Sci Biotechnol Pharm Res.* 2013;2(2):66-71.
30. Odo CE, Nwodo OF, Joshua PE, Ugwu OP, Okonkwo CC. Acute toxicity investigation and anti-diarrhoeal effect of the chloroform–methanol extract of the seeds of *Persea americana* in albino rats. *J Pharm Res.* 2013;6(3):331-5.
31. Adonu CC, Ugwu OPC, Esimone CO, Bawa A, Nwaka AC, Okorie CU. Phytochemical analyses of the methanol, hot water, and n-hexane extracts of the aerial parts of *Cassytha filiformis* (Linn) and leaves of *Cleistopholis patens. Res J Pharm Biol Chem Sci.* 2013;4:1143-9.
32. Orji OU, Ibiam UA, Aja PM, Ugwu P, Uraku AJ, Aloke C, et al. Evaluation of the phytochemical and nutritional profiles of *Cnidoscolus aconitifolius* leaf collected in Abakaliki, South East Nigeria. *World J Med Sci.* 2016;13(3):213-7.
33. Offor CE, Ugwu PC, Okechukwu PM, Igwenyi IO. Proximate and phytochemical analyses of *Terminalia catappa* leaves. *Eur J Appl Sci.* 2015;7(1):9-11.
34. Nwali BU, Egesimba GI, Ugwu PCO, Ogbanshi ME. Assessment of the nutritional value of wild and farmed *Clarias gariepinus. Int J Curr Microbiol Appl Sci.* 2015;4(1):179-82.
35. Afiukwa CA, Igwenyi IO, Ogah O, Offor CE, Ugwu OO. Variations in seed phytic and oxalic acid contents among Nigerian cowpea accessions and their relationship with grain yield. *Cont J Food Sci Technol.* 2011;5(2):40-8.
36. Aja PM, Okechukwu PCU, Kennedy K, Ibere JB, Ekpono EU. Phytochemical analysis of *Senna occidentalis* leaves. *IDOSR J Appl Sci.* 2017;2(1):75-91.
37. Igwenyi IO, Isiguzo OE, Aja PM, Ugwu Okechukwu PC, Ezeani NN, Uraku AJ. Proximate composition, mineral content, and phytochemical analysis of the African oil bean (*Pentaclethra macrophylla*) seed. *Am-Eurasian J Agric Environ Sci.* 2015;15:1873-5.
38. Afiukwa CA, Ugwu OP, Ebenyi LN, Oketa HA, Idenyi JN, Ossai EC. Phytochemical analysis of two wild edible mushrooms, *Auricularia polytricha* and *Pleurotus ostreatus*, common in Ohaukwu area of Ebonyi State, Nigeria. *Res J Pharm Biol Chem Sci.* 2013;4(2):1065-70.
39. Chukwuemeka IM, Udeozo IP, Mathew C, Oraekwute EE, Onyeze RC, Ugwu OPC. Phytochemical analysis of crude ethanolic leaf extract of *Morinda lucida. Int J Res Rev Pharm Appl Sci.* 2013;3(4):470-5.
40. Udeozo IP, Nwaka AC, Ugwu OP, Akogwu M. Anti-inflammatory, phytochemical, and acute toxicity study of the flower extract of *Newbouldia laevis. Int J Curr Microbiol Appl Sci.* 2014;3(3):1029-35.

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

41. Afiukwa CA, Ugwu Okechukwu PC, Ebenyi LN, Ossai EC, Nwaka AC. Phytochemical analysis of three wild edible mushrooms: Coral mushroom, *Agaricus bisporus*, and *Lentinus sajor-caju*, common in Ohaukwu area of Ebonyi State, Nigeria. *Int J Pharmaceutics*. 2013;3(2):410-4.
42. Okechukwu PC, Amasiorah VI. The effects of the crude ethanol root extract and fractions of *Sphenocentrum jollyanum* on hematological indices and glycosylated haemoglobin of streptozotocin-induced diabetic albino rats. *INOSR Sci Res*. 2020;6(1):61-74.
43. Ikechukwu AA, Ibiam UA, Okechukwu PU, Inya-Agha OR, Obasi UO, Chukwu DO. Phytochemistry and acute toxicity study of *Bridelia ferruginea* extracts. *World J Med Sci*. 2015;12(4):397-402.
44. Igwenyi IO, Dickson O, Igwenyi IP, Okechukwu PC, Edwin N, Alum EU. Properties of vegetable oils from three underutilized indigenous seeds. *Glob J Pharmacol*. 2015;9(4):362-5.
45. Ibiam UA, Alum EU, Aja PM, Orji OU, Nwamaka EN, Ugwu OPC. Comparative analysis of chemical composition of *Buchholzia coriacea* ethanol leaf extract, aqueous, and ethyl acetate fractions. *Indo Am J Pharm Sci*. 2018;5(7):6358-69.
46. Onukwuli CO, Izuchukwu CE, Okechukwu PU. Harnessing the potential of indigenous African plants in HIV management: A comprehensive review integrating traditional knowledge with evidence-based medicine. *IDOSR J Biochem Biotechnol Allied Fields*. 2024;9(1):1-11. doi:10.59298/IDOSR/JBBAF/24/91.111.
47. Onukwuli CO, Izuchukwu CE, Okechukwu PU. Exploring phytochemicals for diabetes management: Mechanisms, efficacy, and future directions. *Newport Int J Res Med Sci*. 2024;5(2):7-17. doi:10.59298/NIJRMS/2024/5.2.0717.

CITE AS: Tugonza Akiro F. (2025). Engineering Novel Drug Formulations: Challenges and Opportunities. NEWPORT INTERNATIONAL JOURNAL OF PUBLIC HEALTH AND PHARMACY,6(1):20-26.
https://doi.org/10.59298/NIJPP/2025/612026